Abstract
Background We urgently need answers to basic epidemiological questions regarding COVID-19 infection in pregnant women and newborns. While many national registries, health facilities, and research groups are collecting relevant data, we need a collaborative and methodologically appropriate approach to utilize these data to generate answers.
Methods We propose that a sequential, prospective meta-analysis (PMA) is the best approach to rapidly generate policy and practice-oriented guidelines. As the pandemic is rapidly evolving, studies identified retrospectively through a living systematic review will also be invited to participate. The primary analysis will pool data using a two-stage meta-analysis with generic inverse-variance methods. The meta-analyses will be updated as additional data accrues in each contributing study and as additional studies meet study-specific time or data accrual thresholds for sharing.
Participating Studies At the time of publication, there are 19 studies being conducted in 21 countries that prospectively agreed to pool data for this analysis. Among the 19 included studies, ten are COVID-19 registry studies, seven are cohort or surveillance studies, and two are case-control studies. More than 74,000 pregnant women are expected to contribute to the completed analysis.
Dissemination Protocols and updates will be maintained publicly. Results will be shared with key stakeholders including the World Health Organization (WHO) Maternal, Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Scientific publications will be published in open access journals on an ongoing basis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PROSPERO ID: 188955
Funding Statement
Funded by the Bill & Melinda Gates Foundation grant to Emily Smith (INV-022057) at George Washington University and a grant to Emily Smith via a grant from the Bill & Melinda Gates Foundation to Stephanie Gaw (INV-017035) at University of California San Francisco.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a protocol paper and thus exempt from ethical approval. Ultimately, the meta-analysis study is exempt from human research ethics approval as the study authors will be synthesizing de-identified or aggregate data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: Funded by the Bill & Melinda Gates Foundation grant to Emily Smith (INV-022057) and a grant to Stephanie Gaw (INV-017035).
Conflict of Interest: The authors have none to declare.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.